XERS Stock Overview
A biopharmaceutical company, engages in developing and commercializing therapies in Illinois. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Xeris Biopharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.06 |
| 52 Week High | US$3.64 |
| 52 Week Low | US$1.69 |
| Beta | 1.28 |
| 11 Month Change | 0.99% |
| 3 Month Change | 9.29% |
| 1 Year Change | 75.86% |
| 33 Year Change | 39.73% |
| 5 Year Change | n/a |
| Change since IPO | 29.66% |
Recent News & Updates
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Oct 25Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks
Sep 07
Recent updates
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Oct 25Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks
Sep 07Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company
Jun 04Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Mar 30Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results
Mar 09Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up
Mar 06Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth
Jan 05Xeris Pharmaceuticals Q2 2022 Earnings Preview
Aug 09Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal
Aug 01Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven
May 21Xeris Continues To Execute And Build Long-Term Value Potential
Feb 22Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition
Dec 20Shareholder Returns
| XERS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.9% | -3.8% | -1.0% |
| 1Y | 75.9% | 9.8% | 30.3% |
Return vs Industry: XERS exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: XERS exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| XERS volatility | |
|---|---|
| XERS Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XERS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XERS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 377 | John Shannon | www.xerispharma.com |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.
Xeris Biopharma Holdings, Inc. Fundamentals Summary
| XERS fundamental statistics | |
|---|---|
| Market cap | US$448.74m |
| Earnings (TTM) | -US$63.11m |
| Revenue (TTM) | US$187.36m |
2.4x
P/S Ratio-7.2x
P/E RatioIs XERS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XERS income statement (TTM) | |
|---|---|
| Revenue | US$187.36m |
| Cost of Revenue | US$34.92m |
| Gross Profit | US$152.44m |
| Other Expenses | US$215.55m |
| Earnings | -US$63.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 81.36% |
| Net Profit Margin | -33.69% |
| Debt/Equity Ratio | -816.6% |
How did XERS perform over the long term?
See historical performance and comparison